CeQur closed a $120 million financing round to support its wearable insulin delivery technology.
Horw, Switzerland-based CeQur plans to use the funds to drive growth and accelerate commercial expansion efforts. It aims to scale commercial teams and outreach initiatives to bring Simplicity, its four-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes.
Related: FIRE1 raises $120M for breakthrough heart failure management tech
“We are grateful for the support of our investors as we accelerate our mission to transform diabetes care,” said Brad Paddock, president and CEO of CeQur.
The company said it plans to continue growing its sales force and expand its clinical team. It wants to bring its convenient, discreet and injection-free dosing technology to more people with diabetes. More than 6,000 patients currently use the patch-based bolus insulin delivery device, according to a news release.
“This financing will enable us to reach more patients, expand our commercial footprint, and continue innovating solutions that simplify mealtime insulin management”, said Mike Rubino, CFO of CeQur.
CeQur said it continues to increase and improve pharmacy access to its device. It has struck agreements with numerous Medicare Part-D and State Medicaid programs. Additionally, with manufacturing, the company’s 40,000-square-foot automated cleanroom facility completed all qualifications last year. It plans to manufacture commercial product in 2025.
